Abstract
The management of benign diseases of the breast aims tohalt the progression of fibrocystic transformation and toeliminate the symptoms of pain and breast tenderness.Progestins can be used for this purpose. In a controlled,randomized, double-blind, parallel-group study wetreated 31 women with mastopathy/mastodynia with theprogestins medrogestone (10 mg/day) or dydrogesterone(10 mg/day) from day 14 to day 25 for six cycles.Before, during and at the end of therapy the followingparameters were evaluated: subjective symptoms (pain,tenderness, impairment of daily activities), palpatoryfindings, sonographic diagnosis and sex hormone profiles.Cyclic administration of the low-dose progestinsmedrogestone and dydrogesterone proved to be an effectiveand safe treatment of mastodynia and mastopathy. Theobjective parameters palpatory findings and sonographicimaging of breast nodules and cysts improved in morethan 50% of patients. Improvement was particularlymarked in women with low progesterone levels in thesecond half of the cycle. After six treatment cycles, 75%of the patients treated with dydrogesterone and 86% ofthe patients treated with medrogestone were completelypain-free.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
